Abstract
The recent introduction of a new class of biologic agents in psoriasis has led to important advances in the management of this disease. IL-12 and IL-23 play a key role in the control of malignancies and infections. The development of novel molecules capable of blocking the action of these cytokines has rekindled the debate on whether biologic agents increase the risk of malignancy in patients with psoriasis.In this chapter, we review the safety data for patients who have been treated for 3 or 4 years and the literature on the use of ustekinumab.Based on the available evidence, it can be concluded that patients treated with stekinumab do not have a higher risk of malignancy than the general population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
